Kura Oncology (KURA) Common Equity (2010 - 2026)
Kura Oncology (KURA) posted quarterly Common Equity of $107.9 million for Q1 2026, down 70.39% year-over-year from $364.4 million in Q1 2025, and down 38.05% quarter-over-quarter from $174.1 million in Q4 2025.
Kura Oncology (KURA) Common Equity (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Common Equity for 17 consecutive years, with $107.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 70.39% year-over-year to $107.9 million; the TTM figure through Mar 2026 stood at $107.9 million (down 70.39% YoY), while the FY2025 annual figure was $174.1 million, down 57.9% from the prior year.
- Common Equity slipped to $107.9 million in Q1 2026 per KURA's latest filing, from $174.1 million in the prior quarter.
- Across five years, Common Equity topped out at $505.1 million in Q1 2024 and bottomed at $107.9 million in Q1 2026.
- Historically, Common Equity has averaged $379.5 million across 5 years, with a median of $419.6 million in 2022.
- Annual changes were most pronounced in 2024 — Common Equity gained 27.81% — and 2026, when it plunged 70.39%.
- Kura Oncology's Common Equity stood at $420.3 million in 2022, then fell by 5.47% to $397.3 million in 2023, then grew by 4.12% to $413.6 million in 2024, then sank by 57.9% to $174.1 million in 2025, then sank by 38.05% to $107.9 million in 2026.
- Business Quant data shows KURA's Common Equity at $107.9 million in Q1 2026, $174.1 million in Q4 2025, and $242.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 48.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.43 Mn |
| Mar 31, 2026 | 107.88 Mn |
| Dec 31, 2025 | 174.14 Mn |
| Sep 30, 2025 | 242.54 Mn |
| Jun 30, 2025 | 305.49 Mn |
| Mar 31, 2025 | 364.41 Mn |
| Dec 31, 2024 | 413.64 Mn |
| Sep 30, 2024 | 423.77 Mn |
| Jun 30, 2024 | 466.07 Mn |
| Mar 31, 2024 | 505.08 Mn |
| Dec 31, 2023 | 397.27 Mn |
| Sep 30, 2023 | 429.94 Mn |
| Jun 30, 2023 | 459.68 Mn |
| Mar 31, 2023 | 395.18 Mn |
| Dec 31, 2022 | 420.28 Mn |
| Sep 30, 2022 | 419.62 Mn |
| Jun 30, 2022 | 449.49 Mn |
| Mar 31, 2022 | 476.25 Mn |
| Dec 31, 2021 | 506.61 Mn |
| Sep 30, 2021 | 533.76 Mn |